164 related articles for article (PubMed ID: 37845393)
21. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
22. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis.
Zhang J; Zhang L; Wang J; Zhao J; Zhao X; Zhang C; Han P; Geng C
Hum Cell; 2022 May; 35(3):909-923. PubMed ID: 35179718
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
25. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
26. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
27. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
28. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Fan Y; Wang J; Jin W; Sun Y; Xu Y; Wang Y; Liang X; Su D
Mol Cancer; 2021 Feb; 20(1):25. PubMed ID: 33530981
[TBL] [Abstract][Full Text] [Related]
29. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
30. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.
Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J
J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418
[TBL] [Abstract][Full Text] [Related]
31. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
[TBL] [Abstract][Full Text] [Related]
32. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
[TBL] [Abstract][Full Text] [Related]
33. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.
Han C; Li X; Fan Q; Liu G; Yin J
Aging (Albany NY); 2019 Jul; 11(14):4858-4875. PubMed ID: 31310241
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
36. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.
Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY
Cells; 2021 Sep; 10(10):. PubMed ID: 34685504
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research.
Wang L; Liu D; Wu X; Zeng Y; Li L; Hou Y; Li W; Liu Z
J Cell Physiol; 2018 Oct; 233(10):6603-6612. PubMed ID: 29215701
[TBL] [Abstract][Full Text] [Related]
38. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
39.
Lin TC
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326089
[TBL] [Abstract][Full Text] [Related]
40. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
